Helius Therapeutics: Medicinal Cannabis Firm Enters Voluntary Administration
Auckland-based medicinal cannabis company Helius Therapeutics has entered voluntary administration, a move reflecting the ongoing challenges within Recent Zealand’s emerging cannabis sector. The decision, announced Monday, March 11, 2026, comes despite a recent leadership change aimed at bolstering the company’s position. Helius, founded in 2018, was among the first companies to operate in the country’s medicinal cannabis market, but ultimately succumbed to a combination of high operating costs and a restrictive regulatory landscape.
Navigating a Complex Regulatory Environment
The voluntary administration process, handled by Daniel Stoneman and Neale Jackson of Calibre Partners, will see the company continue to trade at a reduced capacity for the next six weeks to facilitate the sale of existing stock. All manufacturing operations have ceased, and the company’s assets will be liquidated. According to a statement released by Stoneman, the move followed “a sustained period of trading losses driven by high operating costs and a challenging regulatory environment.”
This isn’t simply a company-specific issue. Over the past several years, industry participants in New Zealand have repeatedly called for regulatory reforms to ease the burden on manufacturers. The current rules, they argue, craft it difficult to operate sustainably and scale production effectively. The sector’s struggles highlight the delicate balance between ensuring product safety and fostering a viable commercial environment.
Recent Leadership Change Fails to Stem Losses
Adding a layer of complexity to the situation is the recent appointment of Vicky Taylor as Group CEO of Helius Health, the parent company of both Helius Therapeutics and Elysian Group. Taylor, who joined in late 2025, brought over 20 years of executive leadership experience from roles at companies like moochi, Smartfoods, Coca-Cola Oceania, and Griffins Foods, as noted in a LinkedIn post from October 14, 2025. Helius Therapeutics’ LinkedIn announcement highlighted her expertise in driving business growth and navigating regulated environments. Despite her experience, Taylor was unable to steer the company away from administration.
In a statement, Taylor acknowledged the difficulty of the situation, stating, “This represents an incredibly difficult moment for our team and for the wider medical cannabis industry.” She emphasized the company’s priority of supporting staff and ensuring continued patient care through its clinic network, Cannaplus.
Impact Beyond Helius: Sector-Wide Concerns
While the voluntary administration specifically impacts Helius Therapeutics’ manufacturing operations, the broader implications extend to the New Zealand medicinal cannabis industry as a whole. The failure of one of the sector’s early players serves as a cautionary tale for other companies operating in the space. It underscores the financial risks associated with navigating a nascent and heavily regulated market.
Importantly, the administration does not affect the clinic business operated by Helius Group under the Cannaplus brand. This separation suggests a strategic attempt to protect the patient-facing side of the business from the financial difficulties of the manufacturing arm. Cannaplus will continue to operate, providing access to medicinal cannabis products sourced from other suppliers.
Financial Pressures and the Path to Administration
The core issue driving Helius Therapeutics into administration appears to be financial. The company experienced sustained trading losses, exacerbated by high operating costs. While specific financial figures haven’t been publicly disclosed beyond the general statement of losses, the challenges faced by Helius mirror those reported by other companies in the sector. These include difficulties securing funding, navigating complex licensing requirements, and competing with a developing black market.
The voluntary administration process itself is a legally defined procedure designed to allow a financially distressed company to restructure its affairs or liquidate its assets in an orderly manner. Calibre Partners, as administrators, will assess the company’s financial position, identify creditors, and work to maximize returns for stakeholders. The six-week trading period is intended to generate cash flow through the sale of remaining inventory.
What’s Next for Helius and the New Zealand Cannabis Market?
The immediate future for Helius Therapeutics involves the orderly liquidation of its assets. The East Tāmaki manufacturing facility will be closed, and the company’s remaining stock will be sold off. The fate of the company’s intellectual property, including any patents or proprietary formulations, remains uncertain and will likely be determined during the administration process.
Looking ahead, the Helius situation is likely to intensify calls for regulatory reform within the New Zealand medicinal cannabis industry. Industry advocates will likely leverage this case as evidence of the necessitate for a more streamlined and supportive regulatory framework. As reported by 1News, the sector has been voicing these concerns for some time. The government’s response to these calls will be crucial in determining the future viability of the industry. Further complicating matters is the potential for increased scrutiny of other companies in the sector, as investors and regulators assess the risks associated with the market. MMJDaily too reported on the shutdown, highlighting the challenges facing the sector.
The closure of Helius Therapeutics represents a significant setback for the New Zealand medicinal cannabis industry. While the Cannaplus clinic network will continue to operate, the loss of a key manufacturing player underscores the fragility of the sector and the urgent need for a more sustainable regulatory environment. The coming months will be critical in determining whether the industry can overcome these challenges and realize its potential.